METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody combo shows promise against tough cancers
Disease control TerminatedThis study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
Disease control TerminatedThis early-phase trial tests a personalized cell therapy for people with metastatic pancreatic cancer. A patient's own T-cells are genetically modified to recognize and attack mesothelin, a protein found on many pancreatic cancer cells. Before receiving the modified cells, patien…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cocktail takes on tough pancreatic cancer
Disease control TerminatedThis early-phase trial is testing whether adding two immunotherapy drugs (botensilimab and balstilimab) to a strong chemotherapy mix plus two oral medications (chloroquine and celecoxib) can help people with metastatic pancreatic cancer that hasn't been treated yet. The study inv…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Pancreatic cancer drug trial halted after just two patients
Disease control TerminatedThis phase 2 trial aimed to see if the drug niraparib could shrink tumors in people with metastatic pancreatic cancer that has certain gene mutations. Only 2 patients were enrolled before the study was terminated early, so we don't have enough information to know if it works. The…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising pancreatic cancer combo trial halted early
Disease control TerminatedThis study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial enrolled 164 adults and aimed to see if the combinations slowed …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Radiation plus chemo for pancreatic cancer pain: trial ends early
Symptom relief TerminatedThis phase 2 trial tested whether adding MR-guided radiation to standard chemotherapy could reduce pain in people with metastatic pancreatic cancer. Only 9 participants were enrolled before the study was terminated early. The main goal was to track pain scores over time, but the …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Ludwig-Maximilians - University of Munich • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC